Victory Capital Management Inc. Purchases 149,699 Shares of Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX)

Key Points

• Victory Capital Management Inc. increased its holdings in AMNEAL PHARMACEUTICALS by 70.9%, owning 360,829 shares valued at approximately $3 million as of its latest SEC filing.
• AMNEAL PHARMACEUTICALS reported $0.19 earnings per share, surpassing analysts' expectations of $0.14, despite a revenue miss of $695.42 million against the projected $714.78 million.
• Analysts have a consensus rating of "Buy" for AMNEAL PHARMACEUTICALS, with an average target price of $11.60.

Victory Capital Management Inc. increased its stake in shares of Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX - Free Report) by 70.9% during the 1st quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 360,829 shares of the company's stock after buying an additional 149,699 shares during the period. Victory Capital Management Inc. owned 0.12% of Amneal Pharmaceuticals worth $3,024,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in AMRX. GAMMA Investing LLC increased its stake in Amneal Pharmaceuticals by 5,975.0% during the 1st quarter. GAMMA Investing LLC now owns 3,159 shares of the company's stock worth $26,000 after purchasing an additional 3,107 shares in the last quarter. Amalgamated Bank boosted its holdings in shares of Amneal Pharmaceuticals by 33.0% in the 1st quarter. Amalgamated Bank now owns 5,511 shares of the company's stock valued at $46,000 after buying an additional 1,367 shares during the last quarter. GF Fund Management CO. LTD. acquired a new stake in shares of Amneal Pharmaceuticals in the 4th quarter valued at approximately $52,000. Straightline Group LLC bought a new stake in Amneal Pharmaceuticals in the 4th quarter valued at $92,000. Finally, Brevan Howard Capital Management LP bought a new stake in Amneal Pharmaceuticals in the 4th quarter valued at $107,000. 31.82% of the stock is owned by institutional investors.

Amneal Pharmaceuticals Stock Down 1.2%

NASDAQ AMRX traded down $0.10 on Thursday, reaching $7.98. The company had a trading volume of 234,017 shares, compared to its average volume of 1,665,346. The stock has a market capitalization of $2.50 billion, a P/E ratio of -199.33 and a beta of 1.06. The company's fifty day moving average is $7.91 and its 200 day moving average is $7.96. Amneal Pharmaceuticals, Inc. has a 52-week low of $6.50 and a 52-week high of $9.48.

Amneal Pharmaceuticals (NASDAQ:AMRX - Get Free Report) last announced its quarterly earnings data on Friday, May 2nd. The company reported $0.19 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.14 by $0.05. The firm had revenue of $695.42 million during the quarter, compared to the consensus estimate of $714.78 million. Amneal Pharmaceuticals had a negative return on equity of 188.26% and a negative net margin of 0.46%. On average, research analysts expect that Amneal Pharmaceuticals, Inc. will post 0.53 EPS for the current year.

Wall Street Analyst Weigh In

Several brokerages have recently commented on AMRX. The Goldman Sachs Group assumed coverage on shares of Amneal Pharmaceuticals in a report on Friday, June 6th. They set a "buy" rating and a $12.00 target price on the stock. Wall Street Zen downgraded shares of Amneal Pharmaceuticals from a "strong-buy" rating to a "buy" rating in a research note on Tuesday, May 13th. Six investment analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the stock currently has a consensus rating of "Buy" and a consensus price target of $11.60.

Amneal Pharmaceuticals Company Profile

Amneal Pharmaceuticals, Inc, together with its subsidiaries, develops, manufactures, markets, and distributes generics, injectables, biosimilars, and specialty branded pharmaceutical products worldwide. The company operates through three segments: Generics, Specialty, and AvKARE. The Generics segment offers immediate and extended release oral solid, powder, liquid, sterile injectable, nasal spray, inhalation and respiratory, biosimilar, ophthalmic, film, transdermal patch, and topical products.